

**Appendix 1- Clean Copy of Amended Title and Specification**

The Title of the Invention is as follows:

Methods for Treating Human Impotence with Nitric Oxide Donor Compounds

The paragraph in the specification at page 1, lines 5-7, now reads as follows:

B<sup>1</sup>  
This is a divisional of Application No. 09/145,143, filed September 1, 1998, issued as U.S. Patent No. 6,294,517, which is a continuation-in-part of U.S. Application No. 08/714,313, filed September 18, 1996, issued as U.S. Patent No. 5,994,294, which is a continuation-in-part of U.S. Application No. 08/595,732, filed February 2, 1996, issued as U.S. Patent No. 5,932,538. This application is also a continuation-in-part of PCT/US97/01294, filed January 28, 1997.

The paragraph in the specification at page 4, lines 14 to 24, now reads as follows:

B<sup>2</sup>  
In another aspect, the invention provides methods for treating human impotence, sexual dysfunctions or enhancing sexual responses in humans, including males and females, comprising administering to an individual in need thereof compositions comprising a therapeutically effective amount of at least one  $\alpha$ -antagonist that is optionally substituted with at least one NO or NO<sub>2</sub> moiety, and at least one compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO<sup>+</sup>) or nitroxyl (NO<sup>-</sup>), or as the neutral species, nitric oxide (NO<sup>•</sup>), and/or at least one compound that elevates levels of endogenous EDRF. The  $\alpha$ -antagonist or  $\alpha$ -antagonist directly or indirectly linked to at least one NO or NO<sub>2</sub> group, and nitric oxide donor can be administered separately or as components of the same composition.

**Appendix 1- Clean Copy of Amended Title and Specification**  
**Application No. 09/478,222**

The paragraph in the specification at page 46, line 14 to page 47, line 4, now reads as follows:

B3

Compounds contemplated for use in the invention are nitric oxide and compounds that release nitric oxide or otherwise directly or indirectly deliver or transfer nitric oxide to a site of its activity, such as on a cell membrane, *in vivo*. As used herein, the term "nitric oxide" encompasses uncharged nitric oxide (NO•) and charged nitric oxide species, particularly including nitrosonium ion (NO<sup>+</sup>) and nitroxyl ion (NO<sup>-</sup>). The reactive form of nitric oxide can be provided by gaseous nitric oxide. The nitric oxide releasing, delivering or transferring compounds, having the structure F-NO wherein F is a nitric oxide releasing, delivering or transferring moiety, include any and all such compounds which provide nitric oxide to its intended site of action in a form active for their intended purpose. As used herein, the term "NO adducts" encompasses any of such nitric oxide releasing, delivering or transferring compounds, including, for example, S-nitrosothiols, S-nitrothiols, O-nitrosoalcohols, O-nitroalcohols, sydnonimines, 2-hydroxy-2-nitroso hydrazines (NONOates), (E)-alkyl-2-((E)-hydroxyimino)-5-nitro-3-hexeneamines or hexeneamides, nitrosoamines, as well substrates for the endogenous enzymes which synthesize nitric oxide. It is contemplated that any or all of these "NO adducts" can be mono- or poly-nitrosylated or nitrosated at a variety of naturally susceptible or artificially provided binding sites for nitric oxide or derivatives which donate or release NO.